In melanoma, targeted therapies based on BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) and MEK inhibitors (trametinib, cobimetinib, binimetinib) aim at reducing the activity of this key signaling cascade (1–4). The gene discussed is MAP2K7; the disease is melanoma.